Explore the words cloud of the CLINGLIO project. It provides you a very rough idea of what is the project "CLINGLIO" about.
The following table provides information about the project.
LAMINAR PHARMACEUTICALS SL
|Coordinator Country||Spain [ES]|
|Total cost||6˙155˙125 €|
|EC max contribution||6˙155˙125 € (100%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2017-12-01 to 2020-11-30|
Take a look of project's partnership.
|1||LAMINAR PHARMACEUTICALS SL||ES (PALMA DE MALLORCA)||coordinator||2˙582˙500.00|
|2||SPECIALIZED MEDICAL SERVICES-ONCOLOGY BV||NL (SCHIPHOL)||participant||1˙212˙500.00|
|3||PRAXIS PHARMACEUTICAL SA||ES (MINANO MAYOR)||participant||1˙103˙500.00|
|4||UNIVERSITY OF NEWCASTLE UPON TYNE||UK (NEWCASTLE UPON TYNE)||participant||238˙750.00|
|5||RESEARCH FUND OF THE HADASSAH MEDICAL ORGANIZATION (R.A)||IL (JERUSALEM)||participant||222˙500.00|
|6||UNIVERSITAT DE LES ILLES BALEARS||ES (PALMA DE MALLORCA)||participant||195˙500.00|
|7||FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA||IT (MILANO)||participant||117˙000.00|
|8||INSTITUT GUSTAVE ROUSSY||FR (VILLEJUIF)||participant||117˙000.00|
|9||THE ROYAL MARSDEN NATIONAL HEALTH SERVICE TRUST||UK (London)||participant||117˙000.00|
|10||UNIVERSITA DEGLI STUDI DI SALERNO||IT (FISCIANO SA)||participant||101˙875.00|
|11||LIPODOM KUTATO FEJLESZTO ES TANACSADO KORLATOLT FELELOSSEGU TARSASAG||HU (SZEGED)||participant||97˙000.00|
|12||LANA MANAGEMENT AND BUSINESS RESEARCH INTERNATIONAL LLC||US (ACTON, MASSACHUSETTS)||participant||50˙000.00|
'Glioma is a rare brain cancer with one of the highest mortality rates. It is considered an orphan disease due to its low prevalence (less than 0.5 cases per 10,000 inhabitants in the EU) and the lack of plausible therapies. Based on the discovery of the lipid proliferation switch (high membrane PE-to-SM molar ratio that enables recruitment of cell growth transducers to the membrane), the SME Lipopharma (leading this application) defined a novel anticancer drug target, the tumor repressor protein sphingomyelin synthase 1 (SMS1). An innovative SMS1 activator, 2OHOA, was designed and showed safety and efficacy in preclinical GLP and non-GLP studies. A first-in-man clinical trial I/IIa (ClinicalTrials.gov identifier #NCT01792310) further demonstrated its safety and efficacy in humans. The European Medicines Agency (EMA) designated 2OHOA orphan drug for the treatment of glioma and approximately half of the patients with glioma submitted to >2 months of treatment showed positive response. The present project aims to perform a clinical phase IIB study to demonstrate 2OHOA’s efficacy against glioblastoma multiforme, the most aggressive form of glioma. In this context, a written formal report from the EMA after scientific advice and protocol assistance (SA/PA-EMA/CHMP/SAWP773534/2014) indicates that 2OHOA would obtain Conditional Marketing Authorisation if this phase-IIB study further demonstrates statistically significant efficacy. In addition this project will further investigate 2OHOA’s safety, mechanism of action and biomarkers for glioblastoma diagnosis, prognosis and response to 2OHOA treatment. These studies will let us (i) know the molecular basis underlying the response to 2OHOA treatment, (ii) define new biomarkers, (iii) design more efficacious personalized treatments and (iv) investigate therapeutic alternatives in patients who do not respond to treatment.'
|Protocols and laboratory manual for miRNAS, mRNA expression and RNAseq||Documents, reports||2020-01-30 10:06:15|
|Consititution of the different management bodies||Documents, reports||2020-01-30 10:06:15|
|Clinical Trial registration number||Demonstrators, pilots, prototypes||2020-01-30 10:06:15|
|Sample protocols for liquid biopsy biomarkers||Documents, reports||2020-01-30 10:06:15|
|Public Web Site and Project Presentation||Other||2020-01-30 10:06:15|
|First regulatory approval of final version of study protocol||Websites, patent fillings, videos etc.||2020-01-30 10:06:15|
|Protocols for protein biomarker determinations||Documents, reports||2020-01-30 10:06:15|
Take a look to the deliverables list in detail: detailed list of CLINGLIO deliverables.
|year||authors and title||journal||last update|
Wessal Massalha, Mark Markovits, Edward Pichinuk, Yael Feinstein-Rotkopf, Mark Tarshish, Kumudesh Mishra, Victoria Llado, Miguel Weil, PabloÂ V. Escriba, Or Kakhlon
Minerval (2-hydroxyoleic acid) causes cancer cell selective toxicity by uncoupling oxidative phosphorylation and compromising bioenergetic compensation capacity
published pages: BSR20181661, ISSN: 0144-8463, DOI: 10.1042/bsr20181661
|Bioscience Reports 39/1||2020-01-30|
Francisca Guardiola-Serrano, Roberto Beteta-GÃ¶bel, Raquel RodrÃguez-Lorca, Maitane Ibarguren, David J. LÃ³pez, Silvia TerÃ©s, MarÃa Alonso-Sande, MÃ³nica Higuera, Manuel Torres, Xavier Busquets, Pablo V. EscribÃ¡
The triacylglycerol, hydroxytriolein, inhibits triple negative mammary breast cancer cell proliferation through a mechanism dependent on dihydroceramide and Akt
published pages: , ISSN: 1949-2553, DOI: 10.18632/oncotarget.26824
Doralicia Casares, Pablo V. EscribÃ¡, Catalina Ana RossellÃ³
Membrane Lipid Composition: Effect on Membrane and Organelle Structure, Function and Compartmentalization and Therapeutic Avenues
published pages: 2167, ISSN: 1422-0067, DOI: 10.3390/ijms20092167
|International Journal of Molecular Sciences 20/9||2020-01-30|
Paula FernÃ¡ndez-GarcÃa, Catalina A. RossellÃ³, Raquel RodrÃguez-Lorca, Roberto Beteta-GÃ¶bel, Javier FernÃ¡ndez-DÃaz, Victoria LladÃ³, Xavier Busquets, Pablo V. EscribÃ¡
The Opposing Contribution of SMS1 and SMS2 to Glioma Progression and Their Value in the Therapeutic Response to 2OHOA
published pages: 88, ISSN: 2072-6694, DOI: 10.3390/cancers11010088
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CLINGLIO" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CLINGLIO" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More
Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired PneumoniaRead More